Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here